Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

Nature

Volumn 547, Issue 7664, 2017, Pages 453-457

  Viswanathan, Vasanthi S ^a   Ryan, Matthew J ^a   Dhruv, Harshil D ^b   Gill, Shubhroz ^a   Eichhoff, Ossia M ^c   Seashore Ludlow, Brinton ^a   Kaffenberger, Samuel D ^d   Eaton, John K ^a   Shimada, Kenichi ^e   Aguirre, Andrew J ^a,f   Viswanathan, Srinivas R ^a,f   Chattopadhyay, Shrikanta ^a   Tamayo, Pablo ^a,g   Yang, Wan Seok ^h   Rees, Matthew G ^a   Chen, Sixun ^a   Boskovic, Zarko V ^a   Javaid, Sarah ⁱ   Huang, Cherrie ^a   Wu, Xiaoyun ^a   Tseng, Yuen Yi ^a   Roider, Elisabeth M ^c   Gao, Dong ^d   Cleary, James M ^f   Wolpin, Brian M ^f   Mesirov, Jill P ^a,g   Haber, Daniel A ^i,j   Engelman, Jeffrey A ^k   Boehm, Jesse S ^a   Kotz, Joanne D ^a   Hon, Cindy S ^a   Chen, Yu ^d   Hahn, William C ^a,f   Levesque, Mitchell P ^c   Doench, John G ^a   Berens, Michael E ^b   Shamji, Alykhan F ^a   Clemons, Paul A ^a   Stockwell, Brent R ^l   Schreiber, Stuart L ^a,j,m   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h ST JOHN'S UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^j HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^k NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^l Och Spine at New York Presbyterian Hospitals   (United States)

^m HARVARD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE; AFIMOXIFENE; ALPHA TOCOPHEROL; ARACHIDONATE LIPOXYGENASE; BUTHIONINE SULFOXIMINE; CHONDROITIN SULFATE IRON; FLUINDOSTATIN; GEFITINIB; GLUTATHIONE PEROXIDASE; LIPID HYDROPEROXIDE; LIPID PEROXIDASE; LIPID PEROXIDE; LONG CHAIN FATTY ACID COENZYME A LIGASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; TRANSCRIPTION FACTOR ZEB1; TRANSFER RNA; TRANSFORMING GROWTH FACTOR BETA; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; CADHERIN; IRON; PHOSPHOLIPID-HYDROPEROXIDE GLUTATHIONE PEROXIDASE; ZEB1 PROTEIN, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; ENZYME; ENZYME ACTIVITY; INHIBITION; METABOLISM; PHOSPHOLIPID; TUMOR; VULNERABILITY;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL DEATH; CELL PLASTICITY; CELL TRANSDIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; EPITHELIAL CANCER CELL LINE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSARCOMA CELL; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID PEROXIDATION; LUNG FIBROBLAST; MCF-7 CELL LINE; MELANOMA CELL; MESENCHYMAL STEM CELL; MESENCHYME CELL; NEUROSECRETORY CELL; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; CELL LINEAGE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; MALE; MELANOMA; MESODERM; METABOLISM; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; PROTEOMICS; REPRODUCIBILITY; TUMOR CELL LINE;

CADHERINS; CELL DEATH; CELL LINE, TUMOR; CELL LINEAGE; CELL TRANSDIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GLUTATHIONE PEROXIDASE; HUMANS; IRON; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; MELANOMA; MESODERM; NEOPLASMS; PROSTATIC NEOPLASMS; PROTEOMICS; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 85026414383     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23007     Document Type: Article

References (35)

1. Hoek, K. S. et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650-656 (2008).
2. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196 (2016).
3. Bu, X., Mahoney, K. M. & Freeman, G. J. Learning from PD-1 resistance: new combination strategies. Trends Mol. Med. 22, 448-451 (2016).
4. Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance Nature 546, 431-435 (2017).
5. Gröger, C. J., Grubinger, M., Waldhör, T., Vierlinger, K. & Mikulits, W. Metaanalysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS ONE 7, e51136 (2012).
6. Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290 (2013).
7. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012).
8. Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317-331 (2014).
9. Dixon, S. J. et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem. Biol. 10, 1604-1609 (2015).
10. Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl Acad. Sci. USA 107, 15449-15454 (2010).
11. Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale smallmolecule sensitivity dataset. Cancer Discov. 5, 1210-1223 (2015).
12. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
13. Rees, M. G. et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 12, 109-116 (2016).
14. Germain, A. R. et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. Bioorg. Med. Chem. Lett. 22, 3571-3574 (2012).
15. Chen, V. W. et al. Pathology and classification of ovarian tumors. Cancer 97 (Suppl), 2631-2642 (2003).
16. Tun, H. W. et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS ONE 5, e10696 (2010).
17. Kryukov, G. V. et al. Characterization of mammalian selenoproteomes. Science 300, 1439-1443 (2003).
18. Warner, G. J. et al. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J. Biol. Chem. 275, 28110-28119 (2000).
19. Nieto, M. A., Huang, R. Y.-J., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21-45 (2016).
20. Javaid, S. et al. Dynamic chromatin modification sustains epithelial- mesenchymal transition following inducible expression of Snail-1. Cell Rep. 5, 1679-1689 (2013).
21. Salt, M. B., Bandyopadhyay, S. & McCormick, F. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 4, 186-199 (2014).
22. Gubelmann, C. et al. Identification of the transcription factor ZEB1 as a central component of the adipogenic gene regulatory network. eLife 3, e03346 (2014).
23. Zhang, P., Sun, Y. & Ma, L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14, 481-487 (2015).
24. Ware, K. E. et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2, e39 (2013).
25. Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176-187 (2014).
26. McKeithen, D., Graham, T., Chung, L. W. K. & Odero-Marah, V. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 70, 982-992 (2010).
27. Cheng, P. F. et al. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biol. 16, 42 (2015).
28. Cohen, I. J. & Wolff, J. E. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr. Blood Cancer 61, 7-10 (2014).
29. Mathow, D. et al. Zeb1 affects epithelial cell adhesion by diverting glycosphingolipid metabolism. EMBO Rep. 16, 321-331 (2015).
30. Song, J. EMT or apoptosis: a decision for TGF-β . Cell Res. 17, 289-290 (2007).
31. Dančík, V. et al. Connecting small molecules with similar assay performance profiles leads to new biological hypotheses. J. Biomol. Screen. 19, 771-781 (2014).
32. Liu, X. et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180, 599-607 (2012).
33. Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B. & Sorger, P. K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006).
34. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783-784 (2014).
35. Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73-80 (2015).